Peripheral arterial disease (PAD) is a hallmark of generalized atherosclerosis. Depending on the specific diagnostic criteria that are being used, the prevalence of PAD may be as high as 30 % in the population of people 70 or more years old. Unfortunately, although PAD is prevalent and has many important consequences for patients, it is often under-detected and under-treated by primary care physicians. The aim of this review is to provide an overview of the available literature on epidemiology and antiplatelets management of PAD patients. In particular, we focus on the "hidden" side of PAD burden, the asymptomatic patients, who are at high risk of negative cardiovascular outcomes. Identification of such PAD patients is therefore an important clinical goal to reduce mortality and morbidity and reduce the social cost of atherosclerotic disease. Early screening of PAD and an evidence-based antithrombotic approach are also discussed as potential strategies to counteract the negative impact of such condition in general population, as well as, in patients with other cardiovascular diseases.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1024/0301-1526/a000369 | DOI Listing |
Alzheimers Dement
December 2024
Alzheimer's Disease Research Center, New York University Langone Health, New York, NY, USA.
Background: Behavioral and psychological symptoms of dementia (BPSD) occur frequently in persons with Alzheimer's disease (PAD). They cause suffering, institutionalization, carepartner distress, depression, burden, and decreased PAD-carepartner quality of life. Brexpiprazole approval advanced the AD treatment armamentarium.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Johns Hopkins University, Baltimore, MD, USA.
Background: Phenotyping Alzheimer's Disease (AD) can be crucial to providing personalized treatment. Several studies have analyzed the use of digital biomarkers to characterize a subject's behavior, usually obtained from a single modality, such as speech. However, combining several modalities in a single study has not been deeply studied.
View Article and Find Full Text PDFUps J Med Sci
January 2025
Centre for Clinical Research, Uppsala University, Västmanland County Hospital, Västerås, Sweden.
Background: Growth differentiation factor 15 (GDF-15) is a robust prognostic biomarker in patients with cardiovascular (CV) disease, and a better understanding of its clinical determinants is desirable. We aimed to study the associations between GDF-15 levels and in outpatients with peripheral arterial disease (PAD).
Methods: An explorative cross-sectional study (Study of Atherosclerosis in Vastmanland, Västerås, Sweden) included 439 outpatients with carotid or lower extremity PAD.
Catheter Cardiovasc Interv
January 2025
Department of Cardiology, Rakuwakai Otowa Hospital, Kyoto, Japan.
Background: Supera interwoven nitinol stents (IWNS) and Eluvia fluoropolymer-based drug-eluting stents (DES) were designed to improve the patency of the femoropopliteal (FP) artery; however, which type of stent yields superior outcomes in calcified FP lesions remains unclear.
Aims: To compare the safety and efficacy of Supera IWNS and Eluvia DES in severely calcified FP lesions.
Methods: This study retrospectively analyzed 257 consecutive patients who underwent endovascular therapy using either IWNS (n = 123) or DES (n = 134) for FP lesions with peripheral arterial calcium scoring system (PACSS) grade 3 or 4 severe calcification between April 2018 and December 2021 at eight cardiovascular centers in Japan.
Cardiovasc Revasc Med
December 2024
Veterans Affairs Boston Healthcare System, West Roxbury, MA, United States of America; Brigham and Women's Hospital, Boston, MA, United States of America; Harvard Medical School, Boston, MA, United States of America. Electronic address:
Introduction: Older patients may be denied endovascular revascularization of the superficial femoral artery (SFA) for peripheral artery disease (PAD) due to concerns of worse limb outcomes than younger patients.
Methods: We assessed adverse outcomes in patients after an index revascularization stratified by age (age < 65, 65-75 years, and > 75 years) from two centers between 2003 and 2011 and followed a median 9 (25 %-75 %: 7, 11) years. Outcomes included major adverse limb events (MALE) or minor repeat revascularization, death, and major adverse cardiac and cerebrovascular events (MACCE).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!